Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1982 2
1983 4
1985 2
1986 1
1987 3
1988 5
1989 3
1990 4
1991 4
1992 4
1993 4
1994 7
1995 6
1996 3
1997 11
1999 3
2000 5
2001 7
2002 8
2003 5
2004 7
2005 10
2006 8
2007 9
2008 8
2009 8
2010 12
2011 8
2012 5
2013 5
2014 7
2015 15
2016 17
2017 18
2018 16
2019 17
2020 21
2021 25
2022 20
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

299 results

Results by year

Filters applied: . Clear all
Page 1
A Review of Autologous Stem Cell Transplantation in Lymphoma.
Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Riaz IB, McBride A, Iftikhar A, Anwer F. Zahid U, et al. Curr Hematol Malig Rep. 2017 Jun;12(3):217-226. doi: 10.1007/s11899-017-0382-1. Curr Hematol Malig Rep. 2017. PMID: 28478586 Free PMC article. Review.
Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease sal …
Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory …
Critical care management of chimeric antigen receptor T-cell therapy recipients.
Shimabukuro-Vornhagen A, Böll B, Schellongowski P, Valade S, Metaxa V, Azoulay E, von Bergwelt-Baildon M. Shimabukuro-Vornhagen A, et al. CA Cancer J Clin. 2022 Jan;72(1):78-93. doi: 10.3322/caac.21702. Epub 2021 Oct 6. CA Cancer J Clin. 2022. PMID: 34613616 Free article. Review.
The development of CAR T-cell therapy represents a prime example for the successful bench-to-bedside translation of advances in immunology and cellular therapy into clinical practice. The currently available CAR T-cell products have shown high response rates and long-term …
The development of CAR T-cell therapy represents a prime example for the successful bench-to-bedside translation of advances in immunology a …
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.
Park JH, Nath K, Devlin SM, Sauter CS, Palomba ML, Shah G, Dahi P, Lin RJ, Scordo M, Perales MA, Shouval R, Tomas AA, Cathcart E, Mead E, Santomasso B, Holodny A, Brentjens RJ, Riviere I, Sadelain M. Park JH, et al. Nat Med. 2023 Jul;29(7):1710-1717. doi: 10.1038/s41591-023-02404-6. Epub 2023 Jul 3. Nat Med. 2023. PMID: 37400640 Clinical Trial.
In preclinical models, anakinra, an IL-1 receptor antagonist (IL-1Ra), reduced immune effector cell-associated neurotoxicity syndrome (ICANS) without compromising anti-CD19 chimeric antigen receptor (CAR) T-cell efficacy. We initiated a phase 2 clinical trial of ana …
In preclinical models, anakinra, an IL-1 receptor antagonist (IL-1Ra), reduced immune effector cell-associated neurotoxicity syndrome (ICANS …
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. Hong D, et al. Sci Transl Med. 2015 Nov 18;7(314):314ra185. doi: 10.1126/scitranslmed.aac5272. Sci Transl Med. 2015. PMID: 26582900 Free PMC article. Clinical Trial.
We describe the preclinical activity and initial clinical evaluation of a class of ASOs containing constrained ethyl modifications for targeting the gene encoding the transcription factor STAT3, a notoriously difficult protein to inhibit therapeutically. ...AZD9150 preclin …
We describe the preclinical activity and initial clinical evaluation of a class of ASOs containing constrained ethyl modifications fo …
Interim FDG-PET Imaging in Lymphoma.
Gallamini A, Zwarthoed C. Gallamini A, et al. Semin Nucl Med. 2018 Jan;48(1):17-27. doi: 10.1053/j.semnuclmed.2017.09.002. Epub 2017 Oct 14. Semin Nucl Med. 2018. PMID: 29195613 Review.
A large body of evidence exists in most lymphoma subtypes stressing the role of iPET for early chemotherapy response during first-line chemotherapy treatment, but an increased number of reports have recently been published focusing on the role of iPET in relapsed or refractory …
A large body of evidence exists in most lymphoma subtypes stressing the role of iPET for early chemotherapy response during first-line chemo …
Cellular Immunotherapy in Lymphoma: Beyond CART Cells.
Gaballa MR, Ramos CA. Gaballa MR, et al. Curr Treat Options Oncol. 2020 Feb 11;21(3):21. doi: 10.1007/s11864-020-0709-3. Curr Treat Options Oncol. 2020. PMID: 32048071 Free PMC article. Review.
Cellular immunotherapy has been rapidly evolving and increasingly utilized in the management of relapsed and refractory lymphoma. CD19-specific chimeric antigen receptor T cells (CARTs) have achieved impressive results in pivotal clinical trials. ...As cellul …
Cellular immunotherapy has been rapidly evolving and increasingly utilized in the management of relapsed and refractory lymphoma …
Expanding the armory for treating lymphoma: Targeting redox cellular status through thioredoxin reductase inhibition.
Wang S, Di Trapani G, Tonissen KF. Wang S, et al. Pharmacol Res. 2022 Mar;177:106134. doi: 10.1016/j.phrs.2022.106134. Epub 2022 Feb 18. Pharmacol Res. 2022. PMID: 35189357 Review.
While the recent availability of specific chemotherapy regimes has resulted in good patient outcomes for some lymphoma subtypes, relapsed and refractory lymphoma is still a challenge that needs to be overcome. ...
While the recent availability of specific chemotherapy regimes has resulted in good patient outcomes for some lymphoma subtypes, relapsed an …
Chimeric antigen receptor T-cell therapies for lymphoma.
Brudno JN, Kochenderfer JN. Brudno JN, et al. Nat Rev Clin Oncol. 2018 Jan;15(1):31-46. doi: 10.1038/nrclinonc.2017.128. Epub 2017 Aug 31. Nat Rev Clin Oncol. 2018. PMID: 28857075 Review.
Chimeric antigen receptor (CAR) T cells are emerging as a novel treatment modality for these patients. Clinical trial data have demonstrated the potent activity of anti-CD19 CAR T cells against multiple subtypes of B-cell lymphoma, including diffuse large-B-cell lym …
Chimeric antigen receptor (CAR) T cells are emerging as a novel treatment modality for these patients. Clinical trial data hav …
Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.
Rummel MJ. Rummel MJ. Semin Hematol. 2008 Jul;45(3 Suppl 2):S7-10. doi: 10.1053/j.seminhematol.2008.07.006. Semin Hematol. 2008. PMID: 18760709 Review.
Bendamustine combined with rituximab in vitro shows synergistic effects against various leukemia and lymphoma cell lines. Clinical trials supporting these results show that bendamustine plus rituximab is highly effective in relapsed and refractory patients with indolent ly …
Bendamustine combined with rituximab in vitro shows synergistic effects against various leukemia and lymphoma cell lines. Clinical tr …
299 results